199 related articles for article (PubMed ID: 2439937)
1. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P- and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat.
Brodin E; Ogren SO; Theodorsson-Norheim E
Neuropharmacology; 1987 Jun; 26(6):581-90. PubMed ID: 2439937
[TBL] [Abstract][Full Text] [Related]
2. Substance P receptors in the rat spinal cord: the effect of GTP and of chronic antidepressant treatment.
Iverfeldt K; Ogren SO; Bartfai T
Acta Physiol Scand; 1988 Feb; 132(2):175-9. PubMed ID: 2852434
[TBL] [Abstract][Full Text] [Related]
3. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system.
Arai H; Emson PC
Brain Res; 1986 Dec; 399(2):240-9. PubMed ID: 2435360
[TBL] [Abstract][Full Text] [Related]
4. Serotonin type-2 receptor mediated regulation of substance P release in the ventral spinal cord and the effects of chronic antidepressant treatment.
Iverfeldt K; Peterson LL; Brodin E; Ogren SO; Bartfai T
Naunyn Schmiedebergs Arch Pharmacol; 1986 May; 333(1):1-6. PubMed ID: 2426604
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute systemic treatment with the 5 HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey.
Rosén A; Franck J; Brodin E
Neuropeptides; 1995 Jun; 28(6):317-24. PubMed ID: 7545268
[TBL] [Abstract][Full Text] [Related]
6. Tachykinin release from rat spinal cord in vitro and in vivo in response to various stimuli.
Linderoth B; Brodin E
Regul Pept; 1988 May; 21(1-2):129-40. PubMed ID: 2455922
[TBL] [Abstract][Full Text] [Related]
7. The effect of selective serotonergic neurotoxin treatment on tachykinin levels in the rat ventral spinal cord.
Franck J; Brodin E; Fried K; Rosén A; Yamamoto Y; Fried G
Neuroscience; 1991; 45(2):339-45. PubMed ID: 1722290
[TBL] [Abstract][Full Text] [Related]
8. Tachykinin multiplicity in rat central nervous system as studied using antisera raised against substance P and neurokinin A.
Brodin E; Lindefors N; Dalsgaard CJ; Theodorsson-Norheim E; Rosell S
Regul Pept; 1986 Feb; 13(3-4):253-72. PubMed ID: 2422706
[TBL] [Abstract][Full Text] [Related]
9. Cortical beta- and alpha 2- adrenoceptor binding, hypothalamic noradrenaline and pineal melatonin concentrations measured at different times of the day after repeated treatment of rats with imipramine, zimeldine, alaproclate and amiflamine.
Ask AL; Fowler CJ; Hall H; Kelder D; Ross SB; Sääf J
Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):16-24. PubMed ID: 3006428
[TBL] [Abstract][Full Text] [Related]
10. Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia.
Ogren SO; Holm AC
J Neural Transm; 1980; 47(4):253-71. PubMed ID: 6446594
[TBL] [Abstract][Full Text] [Related]
11. Substance P enhances the release of endogenous serotonin from rat ventral spinal cord.
Franck J; Fried G; Brodin E
Eur J Pharmacol; 1989 Dec; 174(1):85-90. PubMed ID: 2482192
[TBL] [Abstract][Full Text] [Related]
12. Regional distribution and in vivo release of tachykinin-like immunoreactivities in rat brain: evidence for regional differences in relative proportions of tachykinins.
Lindefors N; Brodin E; Theodorsson-Norheim E; Ungerstedt U
Regul Pept; 1985 Mar; 10(2-3):217-30. PubMed ID: 2581287
[TBL] [Abstract][Full Text] [Related]
13. Substance P and neurokinin levels are decreased in the cortex and hypothalamus of alcohol-preferring (P) rats.
Slawecki CJ; Jimenéz-Vasquez P; Mathé AA; Ehlers CL
J Stud Alcohol; 2001 Nov; 62(6):736-40. PubMed ID: 11838908
[TBL] [Abstract][Full Text] [Related]
14. Expression and cellular localization of substance P/neurokinin A and neurokinin B mRNAs in the rat retina.
Brecha NC; Sternini C; Anderson K; Krause JE
Vis Neurosci; 1989 Dec; 3(6):527-35. PubMed ID: 2484823
[TBL] [Abstract][Full Text] [Related]
15. Substance P, neurokinin A and neurokinin B in the ocular response to injury in the rabbit.
Beding-Barnekow B; Brodin E; Håkanson R
Br J Pharmacol; 1988 Sep; 95(1):259-67. PubMed ID: 2464386
[TBL] [Abstract][Full Text] [Related]
16. Effects of acute and chronic treatment with imipramine on 5-hydroxytryptamine nerve cell groups and on bulbospinal 5-hydroxytryptamine/substance P/thyrotropin releasing hormone immunoreactive neurons in the rat. A morphometric and microdensitometric analysis.
Kitayama I; Janson AM; Fuxe K; Agnati LF; Cintra A; Ogren SO; Härfstrand A; Eneroth P; Tsutsumi T; Jonsson G
J Neural Transm; 1987; 70(3-4):251-85. PubMed ID: 2445912
[TBL] [Abstract][Full Text] [Related]
17. Establishment of highly specific radioimmunoassays for neurokinin A and neurokinin B and determination of tissue distribution of these peptides in rat central nervous system.
Tateishi K; Matsuoka Y; Hamaoka T
Regul Pept; 1989 Mar; 24(3):245-57. PubMed ID: 2540512
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the serotonin uptake inhibitor zimelidine elevates substance P levels in rat spinal cord.
Brodin E; Peterson LL; Ogren SO; Bartfai T
Acta Physiol Scand; 1984 Oct; 122(2):209-11. PubMed ID: 6083699
[No Abstract] [Full Text] [Related]
19. Multiple molecular forms of tachykinins in rat spinal cord: a study comparing different extraction methods.
Brodin E; Rosén A; Theodorsson E; Jonczyk A; Sandberg BE; Brodin K
Regul Pept; 1994 Jul; 52(2):97-110. PubMed ID: 7526421
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain.
Lindefors N; Brodin E; Ungerstedt U
Neuropeptides; 1986 Apr; 7(3):265-80. PubMed ID: 2423911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
